On January 4, 2023 Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to modulate the tumor microenvironment to elicit a potent and durable anti-tumor response, reported that Claire Mazumdar, Ph.D., MBA, Chief Executive Officer of Bicara Therapeutics, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA, on Wednesday, January 11, 2023 at 9:30 am PST (Press release, Bicara Therapeutics, JAN 4, 2023, View Source;utm_medium=rss&utm_campaign=bicara-therapeutics-to-present-at-41st-annual-j-p-morgan-healthcare-conference [SID1234625787]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!